Navigation Links
Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error

MORRISTOWN, N.J., Dec. 7, 2012 /PRNewswire/ -- In consultation with the U.S. Food and Drug Administration (FDA), Bayer HealthCare's Consumer Care division has begun a voluntary recall of BRONKAID Caplets Dual Action Formula.  Bayer initiated the recall after identifying that certain information was inadvertently excluded from the product carton label.  It is important to note that this represents a labeling omission only.  The quality of the product itself is not affected.

The affected BRONKAID product lot number can be found on both the interior blister package (in black text adjacent to the expiration date) as well as on the exterior carton containing the blister packaging (embossed on the side panel next to the expiration date)

  • Product Name:  BRONKAID Caplets Dual Action Formula
  • Package size/UPC:  24  caplets ( UPC 300240537879)  and 60 caplets ( UPC 300240537855)
  • Lot #s: see below list
  • This product was sold only in the U.S. at retail outlets nationwide.

    As part of a routine internal review, the company found that certain information was not included in the BRONKAID Drug Facts labeling beginning in January 2012.  This information, which is available on the product website, advises to:

    Stop use and ask a doctor if

  • your asthma is getting worse (see Asthma Alert)
  • you have difficulty sleeping
  • you have a rapid heart beat
  • you have tremors, nervousness, or seizure
  • Consumers who purchased packages of BRONKAID Caplets Dual Action Formula from a lot included in this recall (details below) should be mindful of the above warning as well as the full Drug Fact labeling, but may continue to use the product.  Consumers with questions or an interest in a refund should contact Bayer.  Consumers should contact our Consumer Relations Call Center at 1(800) 986-3307 (available Monday - Friday 8:30AM - 5:30PM eastern standard time.) Any consumer with a medical concern or questions should contact their healthcare provider.

    BRONKAID is indicated for relief of bronchial congestion and mild intermittent asthma symptoms, the latter of which should be first diagnosed by a physician.  For full product information and directions for use, see

    About Bayer HealthCare
    Bayer HealthCare, a subgroup of Bayer AG with annual sales of €17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.

    Bayer HealthCare's Consumer Care Division is headquartered in Morristown, New Jersey, USA. It is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. These include Bayer® Aspirin, ALEVE®, Flanax®/Apronax®, Alka-Seltzer Plus®, Bactine®, RID®, Phillips'® Milk of Magnesia, Midol®, Alka-Seltzer®, Talcid®, Rennie®, Canesten®, Bepanthen®, Bepanthol®, One-A-Day® vitamins, FlintstonesTM vitamins, Supradyn®, Redoxon®, Berocca®, Cal-D-Vita/Elevit®, Vital 50 Plus®, CardioAspirin®.

    BRONKAID Lot Numbers Affected by Voluntary RecallProduct NameLot NumberUPC CodeBRONKAID Dual Action Formula

    24 Coated Caplets


    300240537879BRONKAID Dual Action Formula

    60 Coated Caplets

    NAA0TF3, NAA0TF2, NAA0TF0, NAA0TF1, NAA0TET, NAA0TEW, NAA0TEX, NAA0HHL, NAA0HHK, NAA0HHN, NAA0HHH, NAA0DK5, NAA0DK4, NAA0DK3, NAA0CHE, NAA0CHD, NAA0B3L, NAA0B3K, NAA09XE, NAA09XB, NAA07H2, NAA09XD, NAA07H1, NAA09XA, NAA09XC, NAA07H3, NAA07H4, NAA05BB, NAA05BA, NAA07H0, NAA070D, NAA070C, NAA03PW, NAA05B9, NAA070B, NAA03B8, NAA03B7, NAA02N1, NAA02LW, 244511P, 244501P, 244481P, 244471P, 244491P, 244451P


    SOURCE Bayer HealthCare
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
    2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    3. Bayer Partnership Delivers Industry-First Dose Management Offering
    4. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
    5. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
    6. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
    7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
    8. MediSapiens sapprête à fournir à Bayer HealthCare Pharmaceuticals une nouvelle application informatique en nuage pour analyser et visualiser les données génomiques multidimensionnelles
    9. MediSapiens liefert neue Cloud-Computing-App zur Analyse und Visualisierung multidimensionaler Genomdaten an Bayer HealthCare Pharmaceuticals
    10. MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
    11. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
    Post Your Comments:
    (Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
    (Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
    (Date:11/25/2015)... 25, 2015 --> ... glucose devices was valued at $11,171.1 million in 2014, ... of 5.7% during 2015 - 2022. The global market ... prevalence of diabetes. In addition, the increase in obese ... contributing to the growth of the market. Furthermore, technological ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
    (Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
    (Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
    (Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
    Breaking Medicine News(10 mins):